Edition:
United States

Merus NV (MRUS.OQ)

MRUS.OQ on NASDAQ Stock Exchange Global Market

17.64USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$17.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
10,493
52-wk High
$23.50
52-wk Low
$13.33

Chart for

About

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets... (more)

Overall

Beta: --
Market Cap(Mil.): $329.87
Shares Outstanding(Mil.): 19.39
Dividend: --
Yield (%): --

Financials

  MRUS.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -6.90 -- --
ROI: -70.93 -0.73 12.97
ROE: -147.05 -2.77 14.84

BRIEF-Merus And Vall d'Hebron Institute Of Oncology Announce Research Collaboration

* MERUS AND VALL D'HEBRON INSTITUTE OF ONCOLOGY ANNOUNCE RESEARCH COLLABORATION TO DEVELOP INNOVATIVE BISPECIFIC ANTIBODIES FOR THERAPEUTIC APPLICATIONS IN TREATMENT OF CANCER Source text for Eikon: Further company coverage:

Mar 20 2018

BRIEF-Merus Says Ono Pharma Exercised Option For New Research And License Agreement

* MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES

Mar 14 2018

BRIEF-Merus Announces $55.8 Mln Private Placement Offering

* MERUS ANNOUNCES $55.8 MILLION PRIVATE PLACEMENT OFFERING OF COMMON STOCK

Feb 14 2018

BRIEF-Merus Provides Clinical Updates For Mcla-117 And Mcla-158 Programs

* MERUS PROVIDES CLINICAL UPDATES FOR MCLA-117 AND MCLA-158 PROGRAMS

Jan 04 2018

Appeals court denies Regeneron bid to revive patent case against Merus

A federal appeals court on Tuesday refused to reconsider its ruling that a patent Regeneron Pharmaceuticals Inc asserted against rival Merus NV is unenforceable because it was obtained through deception.

Dec 26 2017

BRIEF-Merus Nv Q3 Loss Per Share Eur 0.81

* MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS

Nov 30 2017

Earnings vs. Estimates